Qurient study shows CDK7 inhibitor Q901 boosts efficacy of TOP1 inhibitor ADCs in preclinical models

PUBT · 1d ago
Qurient study shows CDK7 inhibitor Q901 boosts efficacy of TOP1 inhibitor ADCs in preclinical models
  • Qurient reported a peer-reviewed Science Advances publication on Q901, a selective CDK7 inhibitor, in combination with TOP1 inhibitor-based ADCs.
  • Results have already been presented through the journal publication, not flagged as future conference data.
  • Study outcome showed Q901 boosted tumor response to TOP1 inhibitor drugs by weakening cancer cells’ ability to repair treatment-induced DNA damage.
  • Preclinical evidence supported stronger anti-tumor activity when paired with marketed TOP1i-ADCs, underpinning a combination strategy.
  • Findings also backed a development push toward dual-payload ADCs that package CDK7 and TOP1 inhibitors into one therapy concept.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qurient Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609301500BIZWIRE_USPR_____20260930_BW842516) on September 30, 2026, and is solely responsible for the information contained therein.